Melco International Development Limited 新濠國際發展有限公司 (Incorporated in Hong Kong with limited liability) （於香港註冊成立之有限公司） Website 網址：www.melco-group.com (Stock Code 股份代號：200) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Non-registered Shareholder(s)1 , If you wish to receive a printed copy of the Current Corporate Communication, please complete the Request Form on the reverse side of this letter and return it to the Company's share registrar, Tricor Investor Services Limited, by post using the mailing label p ...

通知信函 各位股東： 致現有登記股東 – 2025年中期報告（「本次公司通訊」）的刊發通知 新濠國際發展有限公 司 （於香港註冊成立之有限公司） 網址：www.melco-group.com （股份代號：200） 不論 閣下早前已向本公司或本公司之股份過戶登記處作出何種收取公司通訊方式的選擇， 閣下均可隨時以合理 時間（為不少於7天）的書面通知發送至本公司之股份過戶登記處卓佳證券登記有限公司，地址為香港夏慤道16號遠 東金融中心17樓或以電郵方式發送至melco200-ecom@vistra.com，更改收取公司通訊的語言版本（英文及╱或中文） 及收取方式（收取印刷本或透過本公司網站閱覽），費用全免。儘管 閣下已選擇（或被視為已同意該選擇）以電子 方式收取日後發出之所有公司通訊，惟倘因任何理由以致以電子方式收取或接收公司通訊時出現困難，本公司均會 因應 閣下之書面要求隨即寄上公司通訊的印刷本，費用全免。 倘 閣下對本函件有任何疑問，請於星期一至星期五（公眾假期除外）上午九時至下午五時致電卓佳證券登記有限公 司之客戶服務熱線，電話號碼為(852) 2980 1333。 代表 新濠國際發展有限公司 公司秘書 梁凱 ...

目錄 | 管理層討論及分析 | 2 | | --- | --- | | 簡明綜合中期財務資料審閱報告 | 29 | | 簡明綜合損益及其他全面收益表 | 31 | | 簡明綜合財務狀況表 | 33 | | 簡明綜合權益變動報表 | 35 | | 簡明綜合現金流量表 | 37 | | 簡明綜合中期財務資料附註 | 39 | | 其他資料 | 67 | | 公司資料 | 91 | 新濠國際發展有限公司 | 二零二五年中期報告 1 管理層討論及分析 重要事件及發展 於二零二五年上半年，新濠國際發展有限公司（「新濠國際」或「本公司」）及其附屬公司（統 稱「本集團」）旗下綜合度假村表現強韌。 期內，本集團致力優化營運開支，並策略性地投資於物業升級及打造高端賓客體驗，以 實現平衡增長。其上半年表現反映本集團具備適應市場動態的能力，同時為其遍佈各地 的多元化物業組合的可持續增長奠定基礎。 在中華人民共和國澳門特別行政區（「澳門」），本集團通過具策略性的物業優化工程保持 競爭優勢，提升了訪客量及營運效率。於二零二五年五月煥新歸來的《水舞間》入座率超 乎理想，顯著帶動非博彩收入，並提升澳門作為娛樂目的地的魅力。 2 新濠國際發 ...

根据国家相关政策规定，对于通过仿制药一致性评价的药品品种，在医保支付方面予以适当支持，医疗 机构应优先采购并在临床中优先选用。同品种药品通过仿制药一致性评价的生产企业达到3家以上的， 在药品集中采购等方面不再选用未通过仿制药一致性评价的品种。公司盐酸林可霉素注射液通过仿制药 一致性评价，有利于提升该药品的市场竞争力，对该药品的市场销售产生积极影响。 智通财经APP讯，*ST苏吴(600200.SH)发布公告，近日，公司全资子公司江苏吴中医药集团有限公司下 属分支机构江苏吴中医药集团有限公司苏州制药厂(简称"苏州制药厂")收到了国家药品监督管理局核准 签发的关于"盐酸林可霉素注射液"的《药品补充申请批准通知书》(通知书编号：2025B04321)，该药品 通过仿制药质量和疗效一致性评价。 ...

Group 1 - The stock of *ST Suwu (600200) closed at 0.95 yuan on September 18, 2025, with an increase of 2.15% and a turnover rate of 4.14% [1] - On September 18, 2025, the net outflow of main funds was 246.04 million yuan, accounting for 8.77% of the total transaction amount [1][3] - The company has been under investigation by the China Securities Regulatory Commission (CSRC) since February 26, 2025, for suspected violations of information disclosure [1] Group 2 - The company received an administrative penalty notice on July 13, 2025, for inflating revenue and profits through transactions with related companies, with inflated revenues reported from 2020 to 2023 totaling 49.53 million yuan, 46.85 million yuan, 43.07 million yuan, and 37.67 million yuan, respectively [1] - The inflated profits during the same period were reported as 1.46 million yuan, 2.03 million yuan, 1.99 million yuan, and 2.12 million yuan [1] - The company’s stock has been subject to a delisting risk warning since July 14, 2025, due to the potential for major illegal delisting circumstances [1][3]

Group 1 - The stock of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) closed at 0.95 yuan on September 18, 2025, with a market capitalization of 675 million yuan, reflecting a 2.15% increase from the previous trading day [1] - The stock experienced a trading volume of 28.05 million yuan and a turnover rate of 4.14% on the same day [1] Group 2 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. issued its eleventh risk warning regarding the potential for major illegal forced delisting due to suspected violations of information disclosure [2] - The company has been under investigation by the China Securities Regulatory Commission (CSRC) since February 26, 2025, for alleged violations [2] - The company’s subsidiaries were found to have inflated revenue, costs, and profits through transactions with related companies, with inflated revenues reported from 2020 to 2023 totaling approximately 494.26 million yuan, 468.51 million yuan, 430.75 million yuan, and 376.66 million yuan, representing 26.46%, 26.39%, 21.26%, and 16.82% of the respective reported revenues [2] - The inflated total profits during the same period amounted to approximately 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan [2] - The stock has been subject to delisting risk warnings since July 14, 2025, and if formal penalties confirm delisting criteria, the stock will be terminated from listing [2]

Core Viewpoint - Melco International Development (00200) has announced a new operational agreement for its subsidiary, Melco Leisure, with Zhi Zhi Imaging, focusing on establishing a private hospital specializing in imaging and diagnostic medical services at the Melco Leisure Integrated Resort, effective from January 1, 2025 [1] Group 1 - The operational agreement grants Zhi Zhi Imaging the rights to operate the private hospital within the Melco Leisure Integrated Resort [1] - The initial term of the agreement will commence from the transaction start date, tentatively set for October 1, 2025, and will last until November 30, 2034 [1] - The agreement includes provisions for two renewal periods, each lasting five years, subject to mutual consent from both parties [1]

Core Viewpoint - The company Melco International Development Limited (00200) has entered into an operational agreement with Zhi Zhi Imaging for a private hospital focused on imaging and diagnostic medical services at the Studio City resort, effective from January 1, 2025 [1] Group 1 - The agreement grants Zhi Zhi Imaging the rights to operate the private hospital within the Studio City integrated resort [1] - The initial term of the agreement is from the start date of the transaction, tentatively set for October 1, 2025, until November 30, 2034 [1] - The agreement can be renewed for two additional terms, each lasting five years, upon mutual consent of the parties involved [1]

格隆汇9月16日丨新濠国际发展(00200.HK)宣布，于2025年9月16日，公司的附属公司新濠影汇商业与卓 智影像订立新濠影汇营运协议，自2025年1月1日起生效，据此，新濠影汇商业授予卓智影像权利在新濠 影汇综合度假村经营一所专注于影像及诊断医疗服务的私家医院，协议初步期限自交易开始日期(暂定 为2025年10月1日)起至2034年11月30日止，经订约各方相互同意可重续两期，每期为五年。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 新濠國際發展有限公 司 （於香港註冊成立之有限公司） 網址：www.melco-group.com （股份代號：200） 公佈 持續關連交易 新濠影滙營運協議 董事會欣然宣佈，於二零二五年九月十六日，本公司之附屬公司新濠影匯商業 與卓智影像訂立新濠影滙營運協議，自二零二五年一月一日起生效，據此，新 濠影匯商業授予卓智影像權利在新濠影滙綜合度假村經營一所專注於影像及診 斷醫療服務之私家醫院，協議初步期限自交易開始日期（暫定為二零二五年十 月一日）起至二零三四年十一月三十日止，經訂約各方相互同意可重續兩期，每 期為五(5)年。 上市規則之涵義 於本公佈日期，卓智影像由Zedra Asia Limited間接持有約40.63%權益，而Zedra Asia Limited為一個全權家族信託之受託人，該信託之受益人包括何猷龍先生及 其家庭成員。因此，根據上市規則第十四A章，卓智影像為本公司主席、行政總 裁兼執行董事 ...